GSK-208136/013 (MeMuRu-OKA-013)

Study to assess immunogenicity and safety of one dose of GSK Biologicals’ live attenuated MMRV vaccine, co-administered with a booster dose of the GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine
Combined Measles, Mumps, Rubella, Varicella Vaccine
208136/013 (MeMuRu-OKA-013)
Measles; Mumps; Rubella; Varicella
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2015